Silencing of phosphoglucose isomerase/autocrine motility factor decreases U87 human glioblastoma cell migration

International Journal of Molecular Medicine

Volumn 37, Issue 4, 2016, Pages 998-1004

  Li, Yang ^a   Wei, Zhenqing ^a   Dong, Bin ^a   Lian, Zhigang ^a   Xu, Yinghui ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma; Metastasis; Phosphoglucose isomerase autocrine motility factor; Side population cells; Tumor growth

Indexed keywords

GLUCOSE 6 PHOSPHATE ISOMERASE; HOE 33342; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SOX2; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ARTICLE; ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE SILENCING; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMORSPHERE FORMATION ASSAY; WESTERN BLOTTING; WOUND HEALING ASSAY; CELL MOTION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENETICS; GLIOBLASTOMA; PATHOLOGY; RNA INTERFERENCE; RNAI THERAPEUTICS; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; GLIOBLASTOMA; GLUCOSE-6-PHOSPHATE ISOMERASE; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; SOXB1 TRANSCRIPTION FACTORS;

EID: 84960533135     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2500     Document Type: Article

References (37)

1. Brandes AA, Tosoni A, Franceschi E, Reni M, Gatta G and Vecht C: Glioblastoma in adults. Crit Rev Oncol Hematol 67: 139-152, 2008.
2. Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G and Group EGW; ESMO Guidelines Working Group: High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 (Suppl 3): iii93-iii101, 2014.
3. Sanai N, Alvarez-Buylla A and Berger MS: Neural stem cells and the origin of gliomas. N Engl J Med 353: 811-822, 2005.
4. Yadav AK, Renfrow JJ, Scholtens DM, Xie H, Duran GE, Bredel C, Vogel H, Chandler JP, Chakravarti A, Robe PA, et al: Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 302: 276-289, 2009.
5. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
7. Tanizaki Y, Sato Y, Oka H, Utsuki S, Kondo K, Miyajima Y, Nagashio R and Fujii K: Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma. Pathol Int 56: 510-515, 2006.
8. Watanabe H, Takehana K, Date M, Shinozaki T and Raz A: Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. Cancer Res 56: 2960-2963, 1996.
9. Niinaka Y, Paku S, Haga A, Watanabe H and Raz A: Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 58: 2667-2674, 1998.
10. Haga A, Niinaka Y and Raz A: Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein. Biochim Biophys Acta 1480: 235-244, 2000.
11. Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, Ohwada S, Raz A and Yokota J: The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 456: 295-300, 1999.
12. Funasaka T, Haga A, Raz A and Nagase H: Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem Biophys Res Commun 285: 118-128, 2001.
13. Funasaka T, Haga A, Raz A and Nagase H: Autocrine motility factor secreted by tumor cells upregulates vascular endothelial growth factor receptor (Flt-1) expression in endothelial cells. Int J Cancer 101: 217-223, 2002.
14. Funasaka T, Haga A, Raz A and Nagase H: Tumor autocrine motility factor induces hyperpermeability of endothelial and mesothelial cells leading to accumulation of ascites fluid. Biochem Biophys Res Commun 293: 192-200, 2002.
15. Haga A, Funasaka T, Niinaka Y, Raz A and Nagase H: Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 107: 707-714, 2003.
16. Romagnoli A, Oliverio S, Evangelisti C, Iannicola C, Ippolito G and Piacentini M: Neuroleukin inhibition sensitises neuronal cells to caspase-dependent apoptosis. Biochem Biophys Res Commun 302: 448-453, 2003.
17. Tsutsumi S, Hogan V, Nabi IR and Raz A: Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res 63: 242-249, 2003.
18. Tsutsumi S, Yanagawa T, Shimura T, Fukumori T, Hogan V, Kuwano H and Raz A: Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem 278: 32165-32172, 2003.
19. Yu FL, Liao MH, Lee JW and Shih WL: Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3. Biochem Biophys Res Commun 314: 76-82, 2004.
20. Funasaka T, Hu H, Yanagawa T, Hogan V and Raz A: Downregulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res 67: 4236-4243, 2007.
21. Feuring-Buske M and Hogge DE: Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38- progenitor cells from patients with acute myeloid leukemia. Blood 97: 3882-3889, 2001.
22. Kim MC, D'Costa S, Suter S and Kim Y: Evaluation of a side population of canine lymphoma cells using Hoechst 33342 dye. J Vet Sci 14: 481-486, 2013.
23. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996.
24. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H and Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7: 1028-1034, 2001.
25. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA and Brenner MK: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004.
26. Kondo T, Setoguchi T and Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101: 781-786, 2004.
27. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M and Goodell MA: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173, 2001.
28. Vermeulen L, Sprick MR, Kemper K, Stassi G and Medema JP: Cancer stem cells - old concepts, new insights. Cell Death Differ 15: 947-958, 2008.
29. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
30. Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, et al: SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511: 246-250, 2014.
31. Brafman DA, Moya N, Allen-Soltero S, Fellner T, Robinson M, McMillen ZL, Gaasterland T and Willert K: Analysis of SOX2-expressing cell populations derived from human pluripotent stem cells. Stem Cell Rep 1: 464-478, 2013.
32. Bani-Yaghoub M, Tremblay RG, Lei JX, Zhang D, Zurakowski B, Sandhu JK, Smith B, Ribecco-Lutkiewicz M, Kennedy J, Walker PR, et al: Role of Sox2 in the development of the mouse neocortex. Dev Biol 295: 52-66, 2006.
33. Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, Vezzani A, Ottolenghi S, Pandolfi PP, Sala M, DeBiasi S and Nicolis SK: Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 131: 3805-3819, 2004.
34. Graham V, Khudyakov J, Ellis P and Pevny L: SOX2 functions to maintain neural progenitor identity. Neuron 39: 749-765, 2003.
35. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE and Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57, 2000.
36. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X and Holland EC: Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 12: 889-901, 2003.
37. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS and Pieper RO: Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61: 6674-6678, 2001.